Bispecific anti-CD20/22 antibodies inhibit B-cell lymphoma proliferation by a unique mechanism of action

Combination immunotherapy with anti-CD20 and anti-CD22 mAbs shows promising activity in non-Hodgkin lymphoma. Therefore, bispecific mAbs (bsAbs) were recombinantly constructed from veltuzumab (humanized anti-CD20) and epratuzumab (humanized anti-CD22) and evaluated in vitro and in vivo. While none o...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Qu, Zhengxing, Goldenberg, David M., Cardillo, Thomas M., Shi, Victoria, Hansen, Hans J., Chang, Chien-Hsing
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2008
Gaiak:
Neoplasia
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2234056/
https://ncbi.nlm.nih.gov/pubmed/18025153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2007-08-110072
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak